BAT's Glo Sees Strong Global Growth in 2022

Feb.16.2023

BAT's 2022 report reveals Glo's growth: global market share of 19.4%, 24.3% revenue increase, and 30% growth in consumers.

Recently, British American Tobacco (BAT) released its 2022 annual report. The report disclosed operational data for BAT's Glo product in 2022.

Report Reveals Global Market Outlook for Glo in 2022:

Glo's market share has reached 19.4%, a year-on-year increase of 1.4%. Glo's global revenue has grown by 24.3% or 26.7% and is expected to continue to grow in the second half of 2022. The number of Glo's consumers has increased by 2 million, reaching 8.8 million, a growth of 30%. Glopod's sales have grown by 25.6%, surpassing the industry growth rate of 15%. Glo's share of the tobacco market (FMC and THP combined) has reached 7.4%, an increase of 0.6% compared to 2021.

In 2022, Glo's sales performance in its key markets is as follows:

Glo, a tobacco heating product (THP) produced by British American Tobacco (BAT), has seen an increase in its market share in Japan and Europe. In Japan, a shift in consumer preference from traditional cigarettes to THPs has boosted Glo's market share (combining both traditional tobacco and THPs) to 7.4% in 2021, representing a 0.6% growth from the previous year. Meanwhile, in Europe, Glo's sales have grown by 33.8% leading to a continued strong increase in revenue by 57.3% or 53.3% (at a fixed exchange rate). The region currently accounts for over 54% of BAT's global THP volume (excluding Russia, which accounts for 43%) and 51% of BAT's global THP revenue (excluding Russia, which is 41%). Sources:

A new category acceleration will boost profitability until 2024.

#Europe #United Kingdom #Market #Disposable e-cigarettes #Global #British American Tobacco (BAT)

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model

The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.

Regulations

Dec.20

Sarawak Cabinet Approves Gradual Ban on Vape Products to Curb Rising Youth Use

The Sarawak Cabinet has agreed to implement a phased ban on vape products amid growing concern over rising use among youths. Welfare, Community Wellbeing, Women, Family and Childhood Development Minister Datuk Seri Fatimah Abdullah said the move demonstrates the state’s firm commitment to safeguarding young people’s health and future.

Nov.17 by 2FIRSTS.ai

BAT Korea Launches Year-End Promotion for “glo hyper” as Demand for Odorless Heated Tobacco Rises

BAT Rothmans has announced a year-end promotion for its “glo hyper” heated tobacco series in response to growing consumer demand for odorless devices during the cold season. As indoor activity rises, more smokers are shifting to heated tobacco products that produce less smell and ash. Government data show HNB sales grew 8.3% last year, accounting for 18.4% of the tobacco market.

Nov.12 by 2FIRSTS.ai

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement

President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.